News | February 28, 2023
Sanofi reaffirms commitment to rare diseases in India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Twelve hospitals across India will be part of the network which will support the trial in India
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The partnership is announced at Aero India 2023, Bangalore
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Subscribe To Our Newsletter & Stay Updated
